Clinical trials: Rapid Response System, open to volunteers
Metastatic Spinal Cord Compression
To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compression (MSCC) on the Magnetic Resonance Linear Accelerator (MRL) in a Single Appointment and Compare it to the Standard of Care Radiotherapy Pathway
The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT)…
- Trial name
- RESONATE (NCT06965101)
- Testing
- Radiotherapy to the spine in a single appointment
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- The Christie NHS Foundation Trust
IBD (Inflammatory Bowel Disease)
E-nose in Evaluating Colitis Activity
The goal of this observational study is to learn whether a rapid stool-based imaging test can help monitor inflammatory bowel disease (IBD) in children.
- Trial name
- SPECTROS (NCT07781215)
- Testing
- Differential Mobile Spectrometry analysis of the stool
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Chronic Spontaneous Urticaria (CSU)
A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines.
- Trial name
- NCT07665996
- Testing
- TLL-018
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Penicillin Allergy, Hypersensitivity, Immediate
Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels
The aim of this clinical trial is to analyze the negative predictive capacity and safety of risk-stratified direct drug provocation tests for patients with self-reported penicillin allergies.
- Conditions
- Penicillin Allergy, Hypersensitivity, Immediate, Hypersensitivity, Delayed, Hypersensitivity Response
- Trial name
- NCT06755281
- Testing
- Direct Oral challenge, standard of care
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Deniz Göcebe
Pediatric ALL, Sepsis
Evaluation of Pediatric eCART Implementation
This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pediatric eCART), a clinical…
- Trial name
- NCT06771830
- Testing
- Pediatric eCART
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Wisconsin, Madison
Status Epilepticus, Coma
Rapid-Response EEG in Children With Suspected Status Epilepticus
Seizures are common in children (~350 per 100,000 patients per year) and require immediate medical attention. If the seizure is prolonged (> 5 minutes) it is called status epilepticus and delayed treatment leads to higher risk in…
- Trial name
- RECS (NCT06564662)
- Testing
- Rapid Response EEG
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Children's Hospital at Montefiore
Interstitial Lung Disease, Myositis
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD).
- Trial name
- NCT07775235
- Testing
- Immunosuppressant Regimen
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- Singapore General Hospital
Sepsis, Septic Shock
Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients
NUROPI is a single-centre, prospective, non-interventional study in the Intensive Care Unit (ICU) of Erasme Hospital (Hôpital Universitaire de Bruxelles, Brussels, Belgium).
- Conditions
- Sepsis, Septic Shock, Cardiac Arrest (CA), Pancreatitis
- Trial name
- NuROPI (NCT07184593)
- Testing
- Plasma H3.1 nucleosome measurement
- Volunteers
- 1,000 people
- Sponsor
- Erasme University Hospital
Hepatitis C, Transmission, Intravenous Drug Abuser
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program, addictology nurse and social worker) and to propose…
- Conditions
- Hepatitis C, Transmission, Intravenous Drug Abuser, Addiction, Alcohol, Addiction Opiate
- Trial name
- SCANVIR (NCT05361603)
- Where
- France
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Amyloidosis; Systemic, AL Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Achievement of complete hematologic response (CHR) is vital for systemic AL amyloidosis. Currently, the CHR rate of daratumumab, bortezomib, and dexamethasone (DBD) is close to 60%.
- Trial name
- NCT06192979
- Testing
- Daratumumab, Bortezomib, Dexamethasone
- Where
- 7 sites in China
- Volunteers
- 41 people
- Sponsor
- Jin Lu, MD
Primary Central Nervous System Lymphoma
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition.
- Trial name
- NCT07851363
- Testing
- HD-MTX-based chemotherapy, BTK inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiaohui Ren
Systemic AL Amyloidosis
Rapid dFLC Response Predict CHR in AL Amyloidosis
Light chain amyloidosis (AL amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems.
- Trial name
- NCT06627309
- Testing
- Dara IV, Bortezomib (drug), Dexamethasone
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Lupus Nephritis
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
- Trial name
- NCT07611214
- Testing
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA)
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aurinia Pharmaceuticals Inc.